Literature DB >> 24150993

Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

George Anderson1, Michael Berk, Olivia Dean, Steven Moylan, Michael Maes.   

Abstract

Accumulating data have led to a re-conceptualization of depression that emphasizes the role of immune-inflammatory processes, coupled to oxidative and nitrosative stress (O&NS). These in turn drive the production of neuroregulatory tryptophan catabolites (TRYCATs), driving tryptophan away from serotonin, melatonin, and N-acetylserotonin production, and contributing to central dysregulation. This revised perspective better encompasses the diverse range of biological changes occurring in depression and in doing so provides novel and readily attainable treatment targets, as well as potential screening investigations prior to treatment initiation. We briefly review the role that immune-inflammatory, O&NS, and TRYCAT pathways play in the etiology, course, and treatment of depression. We then discuss the pharmacological treatment implications arising from this, including the potentiation of currently available antidepressants by the adjunctive use of immune- and O&NS-targeted therapies. The use of such a frame of reference and the treatment benefits attained are likely to have wider implications and utility for depression-associated conditions, including the neuroinflammatory and (neuro)degenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24150993     DOI: 10.1007/s40263-013-0119-1

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  120 in total

1.  IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology.

Authors:  Michael Maes; Ivana Mihaylova; Marta Kubera; Jean-Claude Leunis; Michel Geffard
Journal:  J Affect Disord       Date:  2011-09-17       Impact factor: 4.839

Review 2.  A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness.

Authors:  Michael Maes; Piotr Galecki; Yong Seun Chang; Michael Berk
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-05-12       Impact factor: 5.067

Review 3.  Biological underpinnings of the commonalities in depression, somatization, and Chronic Fatigue Syndrome.

Authors:  George Anderson; Michael Maes; Michael Berk
Journal:  Med Hypotheses       Date:  2012-03-23       Impact factor: 1.538

4.  Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway.

Authors:  Michael Maes; Winfried Rief
Journal:  Psychiatry Res       Date:  2012-02-24       Impact factor: 3.222

Review 5.  Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins.

Authors:  Hitoshi Ohmori; Naoki Kanayama
Journal:  Autoimmun Rev       Date:  2004-12-30       Impact factor: 9.754

6.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

Authors:  M Maes; E Bosmans; R De Jongh; G Kenis; E Vandoolaeghe; H Neels
Journal:  Cytokine       Date:  1997-11       Impact factor: 3.861

7.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Authors:  N Müller; M J Schwarz; S Dehning; A Douhe; A Cerovecki; B Goldstein-Müller; I Spellmann; G Hetzel; K Maino; N Kleindienst; H-J Möller; V Arolt; M Riedel
Journal:  Mol Psychiatry       Date:  2006-02-21       Impact factor: 15.992

8.  A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids.

Authors:  Pao-Yen Lin; Kuan-Pin Su
Journal:  J Clin Psychiatry       Date:  2007-07       Impact factor: 4.384

Review 9.  Antidepressants versus placebo for depression in primary care.

Authors:  Bruce Arroll; C Raina Elley; Tana Fishman; Felicity A Goodyear-Smith; Tim Kenealy; Grant Blashki; Ngaire Kerse; Stephen Macgillivray
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control.

Authors:  Siegfried Kasper; Emmanuelle Corruble; Anthony Hale; Patrick Lemoine; Stuart A Montgomery; Maria-Antonia Quera-Salva
Journal:  Int Clin Psychopharmacol       Date:  2013-01       Impact factor: 1.659

View more
  29 in total

1.  SAHA Improves Depressive Symptoms, Cognitive Impairment and Oxidative Stress: Rise of a New Antidepressant Class.

Authors:  Amir Sasan Bayani Ershadi; Hossein Amini-Khoei; Mir-Jamal Hosseini; Ahmad Reza Dehpour
Journal:  Neurochem Res       Date:  2021-02-12       Impact factor: 3.996

2.  IgM-mediated autoimmune responses to oxidative specific epitopes, but not nitrosylated adducts, are significantly decreased in pregnancy: association with bacterial translocation, perinatal and lifetime major depression and the tryptophan catabolite (TRYCAT) pathway.

Authors:  Chutima Roomruangwong; Buranee Kanchanatawan; Sunee Sirivichayakul; George Anderson; André F Carvalho; Sebastien Duleu; Michel Geffard; Michael Maes
Journal:  Metab Brain Dis       Date:  2017-06-09       Impact factor: 3.584

3.  Increased Root Canal Endotoxin Levels are Associated with Chronic Apical Periodontitis, Increased Oxidative and Nitrosative Stress, Major Depression, Severity of Depression, and a Lowered Quality of Life.

Authors:  Cinthya Gomes; Frederico Canato Martinho; Décio Sabbatini Barbosa; Leonardo Santos Antunes; Helvécio Cardoso Corrêa Póvoa; Thiago Hissnauer Leal Baltus; Nayara Rampazzo Morelli; Heber Odebrecht Vargas; Sandra Odebrecht Vargas Nunes; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

Review 4.  Nitrosative Stress, Hypernitrosylation, and Autoimmune Responses to Nitrosylated Proteins: New Pathways in Neuroprogressive Disorders Including Depression and Chronic Fatigue Syndrome.

Authors:  Gerwyn Morris; Michael Berk; Hans Klein; Ken Walder; Piotr Galecki; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-06-23       Impact factor: 5.590

5.  IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome.

Authors:  Chutima Roomruangwong; Buranee Kanchanatawan; Sunee Sirivichayakul; George Anderson; André F Carvalho; Sebastien Duleu; Michel Geffard; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-04-01       Impact factor: 5.590

6.  Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes.

Authors:  Ole Köhler; Liselotte Petersen; Ole Mors; Christiane Gasse
Journal:  Brain Behav       Date:  2015-05-29       Impact factor: 2.708

7.  Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection.

Authors:  Marilyn Huckans; Bret E Fuller; Hannah Olavarria; Anna W Sasaki; Michael Chang; Kenneth D Flora; Michael Kolessar; Daniel Kriz; Jeanne R Anderson; Arthur A Vandenbark; Jennifer M Loftis
Journal:  Brain Behav       Date:  2013-12-29       Impact factor: 2.708

Review 8.  Erythropoietin Pathway: A Potential Target for the Treatment of Depression.

Authors:  Chongyang Ma; Fafeng Cheng; Xueqian Wang; Changming Zhai; Wenchao Yue; Yajun Lian; Qingguo Wang
Journal:  Int J Mol Sci       Date:  2016-05-06       Impact factor: 5.923

Review 9.  Protective Effects and Network Analysis of Ginsenoside Rb1 Against Cerebral Ischemia Injury: A Pharmacological Review.

Authors:  Weijie Xie; Xinyue Wang; Tianbao Xiao; Yibo Cao; Yumei Wu; Dongsheng Yang; Song Zhang
Journal:  Front Pharmacol       Date:  2021-07-02       Impact factor: 5.810

10.  The use of statins for the treatment of depression in patients with acute coronary syndrome.

Authors:  S W Kim; K Y Bae; J M Kim; I S Shin; Y J Hong; Y Ahn; M H Jeong; M Berk; J S Yoon
Journal:  Transl Psychiatry       Date:  2015-08-18       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.